Abstract
Rheumatoid arthritis (RA) is a chronic rheumatic disease, characterized by erosive and destructive arthritis, representing an important cause of disability. Interstitial lung disease is not a rare event and can be aggravated by several immunosuppressive medications. Methotrexate, once seen as a drug associated with interstitial pneumonitis, is now seen as an agent capable of slowing or preventing the progression of lung disease related to rheumatoid arthritis. Anti-TNFs currently represent the class with the greatest impact on the course of pulmonary disease in RA, with a significant increase in mortality. Among the immunobiological agents, abatacept and Rituximab stand out in relation to the pulmonary safety profile.
Reference17 articles.
1. 1. Mota LMH, Cruz BA, Brenol CV, Pereira IA, Fronza LSR, Bertolo MB, et al. Consenso da Sociedade Brasileira de Reumatologia 2011 para o diagnóstico e avaliação inicial da artrite reumatoide. Rev Bras Reumatol. 2011; 51: 207-219.
2. 2. Smolen JS, Landewé RBM, Bijlsma JWJ, Dougados M, Kerschbaumer A, McInnes IB, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79: 685-699.
3. 3. Flieder DB, Travis WD. Pathologic characteristics of drug-induced lung disease. Clin Chest Med. 2004; 25: 37-46.
4. 4. Melo AK, Silva ADP, Uliana FK, Laurindo IMM, Carvalho CRR, Kairalla RA. Doença pulmonar em pacientes com artrite reumatoide: avaliação radiográfica e espirométrica. J Bras Pneumol. 2015; 41: 331-342.
5. 5. Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic Manifestations of Rheumatoid Arthritis. Clin. Chest Med. 2019; 40: 545-560.